| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | Nucleotide added artificial milk and production thereof | JP19985382 | 1982-11-16 | JPS58216647A | 1983-12-16 | ANJIERU JIRU; RUISU BARUDERUDE |
| 82 | 저당함량 감미제 및 이를 포함하는 식품 조성물 | KR20160089821 | 2016-07-15 | KR20180008045A | 2018-01-24 | BAE CHUL SUB; LEE JI HANG; JEONG HAE SEOK |
| 본명세서에는혼합당및 고감미료의혼합기술을이용한저당함량감미제및 이를포함하는식품조성물에관한것으로, 구체적으로는액상과당, 설탕, 물엿및 올리고당중에서선택되는어느둘 이상을포함하는당과수크랄로스, 스테비올배당체및 효소처리스테비아에서선택되는어느둘 이상을포함하는고감미료를혼합하여설탕및 액상과당과유사한관능을보유한저당함량감미제를제조함으로써, 음료, 유제품, 액상커피, 소스, 잼류및 제과등의식품에감미제원료로사용하여설탕또는액상과당만사용한기존제품대비하여관능적차이가없이당함량을유용하게감소시킬수 있는효과가있다. | ||||||
| 83 | 아기 급식용 포뮬라 및 시스템 | KR1020057014737 | 2004-02-09 | KR101092826B1 | 2011-12-12 | 싱할아툴; 루카스알란 |
| 포뮬라 100ml 당 0.5 내지 1.00g의단백질및 포뮬라 100ml 당 25 내지 50 킬로칼로리를포함하는, 장기적인건강에유익한생후첫 2주동안아기에게급식하기위한유아급식용포뮬라및 예컨대 14개인, 복수의구획을갖고각 용기가아기의일일급식요구량을포함하는용기. | ||||||
| 84 | 당화 우유 및 그것의 용도 | KR1020097024505 | 2008-04-24 | KR1020100017337A | 2010-02-16 | 엘리오트,로버트,바틀렛 |
| A ''sleep milk'' including peptides having a soporific effect on humans or other mammals uses milk proteins from cows homozygous for the A1 allele for beta-casein. Exposing the milk or the proteins to a glycation-enhancing process substantially increases the half-life of the resulting peptides like beta-casomorphin-7 after ingestion, hydrolysis in the gut and absorbtion-through the gut wall. The sleep milk is made by glycating A1 milk within a modified UHT process in the presence of carbohydrates like ascorbic acid. The soporific effect of the resulting product is estimated by measurement of the glycation products. | ||||||
| 85 | 유산균(젖산균)이 함유된 조제분유와 이유식 | KR1020040117551 | 2004-12-28 | KR1020050012212A | 2005-01-31 | 임수현 |
| PURPOSE: Powdered baby formula and baby food containing dried powder and granules of lactic acid bacteria are provided. They promote the digestion and absorption of various nutrients and have an intestinal regulation action and inhibit harmful bacteria in the stomach and intestinal tract. CONSTITUTION: The powdered baby formula and baby food contain 0.0001 to 10% by weight of dried powder and granules of lactic acid bacteria. The lactic acid bacteria contain Lactobacillus reuteri, Bifidobacterium, Streptococcus, Leuconostoc, Pediococcus, Lactococcus, Lactobacillus bulgaricus, Lactobacillus casei and Lactobacillus acidophilus. For an example, powdered body formula for three-month-old baby contains 0.3% by weight of lactic acid, 40 to 60% by weight of whey power, 1 to 3% by weight of mixed edible fat, 10 to 20% by weight of evening primrose oil, 0.2 to 1% by weight of galactooligosaccharide, 0.1 to 1% by weight of lacturose, 0.1 to 0.5% by weight of casein and the like. | ||||||
| 86 | 유아용락토스함유식품조성물 | KR1019980702342 | 1996-09-18 | KR100439601B1 | 2004-09-18 | 하야사와히로토시; 다카하시고우이찌; 난바카주요시; 시미즈타카시; 사야마고우지; 아리쓰카쑤토무; 나구라타이소우; 시미즈요수케 |
| The present invention provides the lactose-containing food compositions for infants for improving the stool color of infants closer to that of breast-fed infants, which comprises the lactose-containing foods for infants of which the only protein source is substantially cow's milk protein and/or a processed product of cow's milk protein modified to be administered to infants, and raffinose added into the foods for infants at a ratio of at least 0.05% (by weight) in a ready-to-use state. This food composition provides foods for infants more suitable for infant growth (infant formula, protein hydrolyzed formula, formula for low-birth-weight infants, follow-up formula, etc.) without causing a green stool which is observed when administering a conventional food for sucking infants, of which the only protein source is substantially cow's milk protein and/or a processed product of cow's milk protein. | ||||||
| 87 | 담즙산염자극 리파아제의 변이체, 이를 코딩하는 데옥시리보핵산 분자, 및 사람을 제외한 형질전환된 포유 동물 | KR1020017007711 | 1994-02-25 | KR100357016B1 | 2002-10-19 | 블렉베르크,라르스; 에들룬트,미카엘; 한손,레나르트; 헤르넬,올레; 룬드베르크,레나르트; 스트룀크비스트,마츠; 퇴르넬,얀 |
| 본발명은담즙산염자극리파아제[Bile Salt-Stimulated Lipase(BSSL); EC 3.1.1.1]의변이체인신규폴리펩티드에관한것이다. 또한, 본발명은상기폴리펩티드를코딩하는 DNA 분자및 상기 DNA 분자로이루어지는부생성물에관한것이다. 또한, 본발명은상기 BSSL 변이체의제조, 및이 BSSL 변이체를발현할수 있는사람을제외한형질전환된포유동물의제조에관한것이다. 더욱이, 본발명은상기형질전환동물, 및상기형질전환된동물유래의젖을포함하는유아식에관한것이다. 또한, 본발명은상기폴리펩티드를포함하는제약조성물, 및약제제조를위한상기폴리펩티드및 DNA 분자의용도에관한것이다. | ||||||
| 88 | 항염증인자, 그의 분리방법 및 이용 | KR1019890702252 | 1989-03-20 | KR100131014B1 | 1998-04-17 | 리이알벡크 |
| 요약 없음 | ||||||
| 89 | THERAPEUTIC COMPOSITION | US15686675 | 2017-08-25 | US20180105582A1 | 2018-04-19 | SIDGI SYED ANWER ABDO HASSON; ALI A. H. AL-JABRI |
| A therapeutic composition can include an herbal composition having solid material or liquid extracts from the solid material of at least one of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The solid material may include one or more of parts or the whole of the stem, the bark, the flowers and the roots of one or more, but preferably all of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The therapeutic composition can include camel milk, alone, or in combination with the herbal composition. The camel milk can be HIV-immunized camel milk. The HIV-immunized camel milk can be obtained by immunizing a camel against HIV by administering to the camel the modified DNA plasmids of SEQ. ID No.: 3 and SEQ ID No.: 4 and obtaining the milk from the immunized camel. | ||||||
| 90 | COMPOSITIONS AND METHODS USING IL-8 TO IMPROVE MILK PRODUCTION AND REPRODUCTIVE HEALTH IN MAMMALS | US15541126 | 2016-01-05 | US20180028615A1 | 2018-02-01 | Rodrigo Carvalho BICALHO |
| The present disclosure provides compositions and methods for improving reproductive health of mammals and increasing milk production from female mammals. The methods involve administering an effective amount of IL-8 to a female mammal such that the reproductive health of the mammal is improved, or milk production from the mammal is increased, or the fat content of the milk is increased. In another aspect the disclosure includes prophylaxis and/or therapy of uterine conditions by administering IL-8 to a female mammal. | ||||||
| 91 | Food Composition | US15028154 | 2014-10-14 | US20160242449A1 | 2016-08-25 | Amedeo Conti; Guido Moro; Laura Cavallarin; Enrico Bertino |
| The subject-matter of the invention is a food composition derived from ass's milk, which is useful in the feeding of premature babies, weak and/or delicate and/or convalescent subjects and/or the elderly. | ||||||
| 92 | HYDROLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | US14877335 | 2015-10-07 | US20160060609A1 | 2016-03-03 | Uwe T. BORNSCHEUER; David WEINER; Tim HITCHMAN; Jonathan LYON; Sirirung WONGSAKUL |
| The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds). The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts, including the manufacture of cosmetics and nutraceuticals. In another aspect, the polypeptides of the invention are used to synthesize enantiomerically pure chiral products. | ||||||
| 93 | PRETERM MILK FORMULA | US13696994 | 2011-05-18 | US20150305383A1 | 2015-10-29 | Gilda Elise Georgi; Bernd Stahl |
| The present invention relates to a protein fortifier for use in varying the amount of protein in preterm infant nutrition, thereby adapting the formula or human milk to the nutritional needs of very low birth weight infants and extremely low birth weight infants. | ||||||
| 94 | Early stimulation of taste and/or flavour acceptance | US13992695 | 2011-12-12 | US08859029B2 | 2014-10-14 | Hugo Weenen; Martine Sandra Alles |
| The invention relates to a kit of parts comprising 2 to 100 containers each containing an infant formula, wherein each infant formula is in a form suitable for administration to an infant and/or toddler or in a form suitable for administration to an infant and/or toddler after admixing with an aqueous liquid, wherein the kit of part comprises at least two different infant formulas which differ from each other in taste and/or flavor by having a different protein fraction or by being a fermented infant formula, wherein each of the different protein fractions is selected from the group consisting of intact milk proteins including cow milk proteins, intact plant proteins including soy protein, hydrolysed proteins, free amino acids, or mixtures of two or more thereof. The invention further relates to the use of such kit of parts for stimulating the acceptance and/or liking of a broad range of fruits, vegetables and/or whole grain cereal products by infants and/or toddlers or later in life. In another aspect, the invention relates to such kit of parts for increasing familiarization with multiple tastes and/or flavors and/or for reducing the risk of food refusal and/or other eating difficulties. In a further aspect the invention relates to such kit of parts for the prevention of obesity, diabetes, atherosclerosis, hypertension, cardiovascular diseases, high blood pressure and cancer at an age of above 36 months. | ||||||
| 95 | Method of, and apparatus for, furnishing information to determine the position of a body | US06514036 | 1983-07-11 | US08842263B1 | 2014-09-23 | William James Montgomery |
| To determine two positional co-ordinates, of a point (D) within a space, a beam (10) a radiation is caused to illuminate a part of the space and is deflected cylindrically over the space, the beam being modulated in phase with the cyclical movement such that the radiation incident upon the point (D) includes enough information to identify the point. Embodiments with rotational (r, θ) and Cartesian (x, y) co-ordinate axes are disclosed. | ||||||
| 96 | Preparation of isolated agonist anti-EDAR monoclonal antibodies | US13791055 | 2013-03-08 | US08741297B2 | 2014-06-03 | Pascal Schneider; Nathalie Dunkel; Stéphane Demotz |
| The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. | ||||||
| 97 | HYDROLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | US13619974 | 2012-09-14 | US20140128590A1 | 2014-05-08 | Uwe T. BORNSCHEUER; David WEINER; Tim HITCHMAN; Jonathan LYON; Sirirung WONGSAKUL |
| The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds). The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts, including the manufacture of cosmetics and nutraceuticals. In another aspect, the polypeptides of the invention are used to synthesize enantiomerically pure chiral products. | ||||||
| 98 | METHOD FOR SCREENING FOR DIET PROVIDING PRODUCTION OF MILK HAVING IMMUNOREGULATORY ACTION | US13809877 | 2012-01-11 | US20130280368A1 | 2013-10-24 | Hirohisa Izumi; Takashi Shimizu; Kazunori Sekine |
| A diet or a substance providing production of breast milk having an immunoregulatory action is screened for by identifying a diet or a substance that increases or decreases amount of mRNA present in milk of a mammal using correlation of mRNA profile in the milk and a diet ingested by the mammal or a substance contained in the diet as an index. | ||||||
| 99 | PREPARATION OF ISOLATED AGONIST ANTI-EDAR MONOCLONAL ANTIBODIES | US13260937 | 2010-03-30 | US20120192296A1 | 2012-07-26 | Pascal Schneider; Nathalie Dunkel; Stephane Demotz |
| The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. | ||||||
| 100 | USE OF NUTRITIONAL COMPOSITIONS INCLUDING LACTOFERRIN IN STIMULATING IMMUNE CELLS | US12980819 | 2010-12-29 | US20120171231A1 | 2012-07-05 | Anja Wittke; Cecilia Munoz; Dattatreya Banavara |
| The present disclosure relates to the use of nutritional compositions including lactoferrin produced by a non-human source in stimulating innate immune cells, such as macrophages, neutrophils, and dendritic cells. | ||||||
QQ群二维码
意见反馈
意见反馈